Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elan Meltdown May End R&D Joint Ventures As Funding Vehicle For Biotech

Executive Summary

The Elan market meltdown is likely to shut off the joint venture route as one avenue for struggling biotech companies to obtain capital

You may also be interested in...



Ivax/Serono Oral MS Therapy Mylinax Efficacy Trials Planned For 2004

Ivax and Serono hope to launch pivotal trials for their oral multiple sclerosis therapy Mylinax (cladribine) in late 2004

Ivax/Serono Oral MS Therapy Mylinax Efficacy Trials Planned For 2004

Ivax and Serono hope to launch pivotal trials for their oral multiple sclerosis therapy Mylinax (cladribine) in late 2004

King/Elan Deal Proceeds; Skelaxin Royalties Will Offset Lower Purchase Price

King will pay Elan royalties on sales of the muscle relaxant Skelaxin under a restructured agreement for Elan's primary care business

Related Content

UsernamePublicRestriction

Register

PS039287

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel